US 11,912,692 B2
Substituted S-alaninate derivatives
Hartmut Beck, Wuppertal (DE); Stefanie Mesch, Basel (CH); Alexandros Vakalopoulos, Hilden (DE); Nils Pfaff, Düsseldorf (DE); Stefanie Zimmermann, Düsseldorf (DE); Markus Follmann, Köin (DE); Elisabeth Kersten, Wuppertal (DE); Guillaume Levilain, Wuppertal (DE); Kartrin Partikel, Wuppertal (DE); Andreas Peter Broehl, Wuppertal (DE); Stefan Heitmeier, Wülfrath (DE); Julia Dietze-Torres, Wuppertal (DE); Lutz Lehmann, Berlin (DE); Kersten Matthias Gericke, Wuppertal (DE); Frank Süßmeier, Munich (DE); Lars Bärfacker, Düsseldorf (DE); Alexander Hillisch, Solingen (DE); Adrian Tersteegen, Wuppertal (DE); Anja Buchmüller, Essen (DE); and Christoph Gerdes, Cologne (DE)
Assigned to Bayer Aktiengesellschaft, Leverkusen (DE)
Filed by BAYER AKTIENGESELLSCHAFT, Leverkusen (DE)
Filed on Aug. 11, 2023, as Appl. No. 18/233,031.
Application 18/233,031 is a continuation of application No. PCT/EP2022/073889, filed on Aug. 29, 2022.
Claims priority of application No. 21194781 (EP), filed on Sep. 3, 2021.
Prior Publication US 2023/0391761 A1, Dec. 7, 2023
Int. Cl. C07D 409/14 (2006.01); A61P 7/02 (2006.01)
CPC C07D 409/14 (2013.01) [A61P 7/02 (2018.01)] 17 Claims
 
1. 2-(1-Methyl-1H-imidazol-2-yl)ethyl 3-[(5-chlorothiophene-2-carbonyl)amino]-N-{2-ethyl-3-[(3S)-3-hydroxy-2-oxopyrrolidin-1-yl]benzene-1-sulfonyl}-S-alaninate of formula (I)

OG Complex Work Unit Chemistry
or a salt thereof, a solvate thereof or a solvate of the salt thereof.